Human Senescence Atlas Turns Aging Into a Mapping Problem
NIH's SenNet atlas does not prove an anti-aging therapy. It gives longevity science a harder measurement layer.
Read the briefing →Frontier 03 / Longevity
Longevity science sits between evidence and ambition.
Vastkind follows aging biology, interventions, biomarkers, and the hard difference between mechanism, animal data, and human proof.
Biomarkers
Interventions
Human proof
Current signal
Latest ↓
Read now
Latest Longevity signals.
Newest longevity stories, with evidence separated from optimism.
David Sinclair's XPRIZE Rejuvenation Plan Has a Proof Problem
The real story is not another anti-aging pill claim. It is whether whole-body rejuvenation can survive XPRIZE's measurement machine.
ER-100 First Human Dosed: The Rejuvenation Test Has Left the Lab
The first human dosing of ER-100 does not prove age reversal. It starts the evidence clock for one of longevity's boldest ideas.
Semaglutide Failed in Alzheimer's. The Bigger Lesson Is About Evidence.
Two major Alzheimer's trials showed semaglutide did not slow clinical decline. The result is a hard lesson in what evidence can and cannot prove.
What Is Longevity Science? How Aging Biology Works, What Human Evidence Shows, and Where Claims Break
Longevity science is real. The hard part is knowing which claims have moved from mechanism to human proof.
The Longevity Industry Has a Measurement Problem
Longevity will not become serious medicine until it proves what its numbers actually mean.
Rapamycin Still Needs Human Proof
Rapamycin has real longevity science behind it. That does not make it a proven anti-aging drug for healthy humans.
Field note
Read the board before it turns into noise.
A compact operating note for Longevity: what changed, what to watch, what to doubt, and where the constraint sits.
Aging becomes an intervention target
The field is moving from vague anti-aging language toward mechanisms, trials, and measurable healthspan claims.
Validated biomarkers
Markers that predict meaningful outcomes, not just marketing narratives.
A biomarker change equals longer life.
Mouse results predict human benefit.
Human proof
Mechanisms and mouse results do not automatically become meaningful human outcomes.
Corridors
Routes around Longevity.
Use these routes when a story crosses into neighboring fields, forces, or reading formats.
Latest corridor story
Human Senescence Atlas Turns Aging Into a Mapping Problem
Latest corridor story
David Sinclair's XPRIZE Rejuvenation Plan Has a Proof Problem
Archive
All Longevity stories, compact.
Use the archive for retrieval; the map above carries the orientation.
David Sinclair's XPRIZE Rejuvenation Plan Has a Proof Problem
The real story is not another anti-aging pill claim. It is whether whole-body rejuvenation can survive XPRIZE's measurement machine.
ER-100 First Human Dosed: The Rejuvenation Test Has Left the Lab
The first human dosing of ER-100 does not prove age reversal. It starts the evidence clock for one of longevity's boldest ideas.
Semaglutide Failed in Alzheimer's. The Bigger Lesson Is About Evidence.
Two major Alzheimer's trials showed semaglutide did not slow clinical decline. The result is a hard lesson in what evidence can and cannot prove.
What Is Longevity Science? How Aging Biology Works, What Human Evidence Shows, and Where Claims Break
Longevity science is real. The hard part is knowing which claims have moved from mechanism to human proof.
The Longevity Industry Has a Measurement Problem
Longevity will not become serious medicine until it proves what its numbers actually mean.
Rapamycin Still Needs Human Proof
Rapamycin has real longevity science behind it. That does not make it a proven anti-aging drug for healthy humans.
Partial Epigenetic Reprogramming Human Trial: Longevity’s Reality Check
ER-100 is a narrow eye-disease trial, but it may be the first real test of whether cellular rejuvenation can survive clinical evidence.
AI + Quantum Longevity Forecast: The Kurzweil Narrative vs the Trial Timeline
Exponential tools are colliding with non-exponential biology.
Longevity Will Not Break the Planet by Itself. Frailty, Emissions, and Inequality Might.
Longevity does not automatically create planetary collapse. The real burden depends on whether extra years are healthy or dependent, low-carbon or resource-heavy, shared or stratified.
Biological Age Testing: What Epigenetic Clocks Can Tell You—and What They Can’t
Epigenetic clocks can be useful research tools and decent trend signals. They become dangerous when people treat them like destiny.
NMN vs NR in 2026: What Human Trials Actually Show
NMN and NR can move NAD-related biomarkers. That does not mean they have already proved meaningful anti-aging outcomes in humans.